Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Quark Pharmaceuticals, a development-stage pharmaceutical company discovering and developing RNA interference-based therapeutics, has announced QPI-1007 as the company's first siRNA drug candidate based on its own intellectual property for a host of novel structures having freedom to operate in the siRNA IP space.
Subscribe to our email newsletter
QPI-1007, which is currently being evaluated in advanced IND enabling preclinical studies as a neuroprotective agent for eye diseases, is the first drug candidate to utilize a novel siRNA structure developed by Quark free of third party IP, said Quark.
The company added that it is utilizing its proprietary structures and intellectual property to develop additional RNAi drug candidates in its robust pipeline.
Daniel Zurr, Quark’s CEO, said: “With more RNAi products in human trials than any other company in the industry, Quark has proven its ability to advance siRNA products from discovery to the clinic. The in vivo results of QPI-1007 mark a new era for Quark.
“We can now rely solely on internally developed novel compositions and proprietary siRNA structures to develop products that have the potential to provide greater efficacy than current treatments. The breadth of our new structures allows us to selectively pick the most efficacious, stable siRNA structure, which is the most suitable for the specific sequence.”